GAL and hepatocellular carcinoma: First, Gal-1 promoted HCC invasion in vitro and in vivo; second, Gal-1 overexpression fostered HCC progression by inducing EMT; and third, forced Gal-1 expression reduced HCC sensitivity to sorafenib.